[go: up one dir, main page]

BRPI0714665A2 - Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer - Google Patents

Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer Download PDF

Info

Publication number
BRPI0714665A2
BRPI0714665A2 BRPI0714665-5A BRPI0714665A BRPI0714665A2 BR PI0714665 A2 BRPI0714665 A2 BR PI0714665A2 BR PI0714665 A BRPI0714665 A BR PI0714665A BR PI0714665 A2 BRPI0714665 A2 BR PI0714665A2
Authority
BR
Brazil
Prior art keywords
cancer
treatment
pharmaceutical agent
prophylaxy
composite
Prior art date
Application number
BRPI0714665-5A
Other languages
English (en)
Inventor
Sakai Nozomu
Imamura Shiniochi
Miyamoto Naoki
Hirayama Takaharu
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of BRPI0714665A2 publication Critical patent/BRPI0714665A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTO, PRó-DROGA, AGENTE FARMACêUTICO, E, MéTODO PARA A PROFILAXIA OU TRATAMENTO DO CáNCER. A presente invenção fornece um derivado heterocíclico fundido tendo uma atividade inibitória de cinase potente e uso deste. Um composto representado pela fórmula (I): em que cada símbolo é como definido no relatório descritivo, excefo um composto particular, ou um sal do mesmo, e um agente farmacêutico contendo o composto ou uma pró-droga do mesmo, que é um inibidor, de cinase (VEGFR, VEGFR2, PDGFR, Raf), um inibidor de angiogênese, um agente para a profilaxia ou tratamento do câncer, um inibidor do crescimento do câncer ou um supressor da metástase do câncer.
BRPI0714665-5A 2006-08-04 2007-08-03 Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer BRPI0714665A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2006213981 2006-08-04
JP2006-213981 2006-08-04
JP2006-331230 2006-12-07
JP2006331230 2006-12-07
JP2007-144072 2007-05-30
JP2007144072 2007-05-30
PCT/JP2007/065681 WO2008016192A2 (en) 2006-08-04 2007-08-03 Fused heterocyclic derivative and use thereof

Publications (1)

Publication Number Publication Date
BRPI0714665A2 true BRPI0714665A2 (pt) 2012-03-13

Family

ID=38996616

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714665-5A BRPI0714665A2 (pt) 2006-08-04 2007-08-03 Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer

Country Status (18)

Country Link
US (4) US8044049B2 (pt)
EP (1) EP2049541B1 (pt)
JP (1) JP5238697B2 (pt)
KR (1) KR20090047509A (pt)
AR (1) AR062207A1 (pt)
AU (1) AU2007279595A1 (pt)
BR (1) BRPI0714665A2 (pt)
CA (1) CA2659971A1 (pt)
CL (1) CL2007002261A1 (pt)
CO (1) CO6150183A2 (pt)
CR (1) CR10607A (pt)
IL (1) IL196799A0 (pt)
MA (1) MA30651B1 (pt)
MX (1) MX2009001349A (pt)
NO (1) NO20090986L (pt)
PE (1) PE20080538A1 (pt)
TW (1) TW200817409A (pt)
WO (1) WO2008016192A2 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2689514C (en) 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
BRPI0815503A2 (pt) * 2007-08-17 2014-09-30 Icagen Inc Composto, composição farmacêutica, e, métodos para modular a atividade de um canal de íon potássio em um indivíduo, para aumentar o fluxo de íon por meio de canais de potássio dependentes da voltagem em uma célula e para tratar, prevenir, inibir ou aliviar um distúrbio ou condição do sistema nervoso central ou periférico
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
UY31676A1 (es) 2008-02-28 2009-09-30 "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
CN101372475B (zh) * 2008-03-19 2012-01-04 南京工业大学 芳杂环取代的二苯脲类衍生物及其用途
EP2444403A1 (en) 2008-04-18 2012-04-25 Shionogi Co., Ltd. Heterocyclic compound having inhibitory activity on PI3K
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
EP2399921B1 (en) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
WO2010067130A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
MX2011006426A (es) 2008-12-24 2011-07-20 Syngenta Ltd Metodos para la preparacion de arilamidas.
EP2396333B1 (en) 2009-02-10 2013-07-03 AstraZeneca AB Triazolo[4,3-b]pyridazine derivatives and their uses for prostate cancer
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5583845B2 (ja) 2010-04-28 2014-09-03 ブリストル−マイヤーズ スクイブ カンパニー イミダゾピリダジニル化合物および癌に対するそれらの使用
CN103841975A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt抑制剂化合物和厄洛替尼的组合以及使用方法
CA2858420A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
US9822418B2 (en) 2013-04-22 2017-11-21 Icahn School Of Medicine At Mount Sinai Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis
US9988386B2 (en) 2013-05-30 2018-06-05 Kata Pharmaceuticals, Inc. Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof
JP2016540773A (ja) * 2013-12-06 2016-12-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
CN106068252B (zh) 2013-12-13 2023-02-03 欧洲化学农业有限公司 含硝化抑制剂的肥料混合物
WO2016086026A1 (en) * 2014-11-26 2016-06-02 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
EP3231427A4 (en) * 2014-12-10 2018-07-11 Senju Pharmaceutical Co., Ltd. Aqueous liquid agent
IL304018A (en) 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
KR20190020343A (ko) 2016-06-29 2019-02-28 오리온 코포레이션 벤조디옥산 유도체 및 이의 약제학적 용도
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018094005A1 (en) * 2016-11-16 2018-05-24 The General Hospital Corporation Myeloperoxidase imaging agents
DE102017201608A1 (de) 2017-02-01 2018-08-02 Eurochem Agro Gmbh 3,4-Dimethylpyrazol enthaltende Mischung und ihre Verwendung
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
US12523663B2 (en) 2019-06-04 2026-01-13 Inserm (Institut National De La Santé Et De La Rescherche Médicale) Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
AU2020346578B2 (en) 2019-09-12 2023-07-13 Nihon Nohyaku Co., Ltd. Agricultural or horticultural insecticide or animal ectoparasite or endoparasite control agent each comprising an imidazopyridazine compound having a substituted cyclopropane-oxadiazole group or a salt thereof as active ingredient, and method for using the insecticide or the control agent
JP7618237B2 (ja) * 2019-10-16 2025-01-21 国立大学法人京都大学 運動神経細胞変性阻害剤
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112023005876A2 (pt) 2020-09-30 2023-05-02 Sumitomo Chemical Co Composto heterocíclico e composição de controle de artrópode nocivo contendo o mesmo
US20220389488A1 (en) * 2021-03-12 2022-12-08 Gt Molecular, Llc Multiplexed genotyping assays with a single probe using fluorescent amplitude tuning
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
CN120187435A (zh) * 2022-10-27 2025-06-20 香港科技大学 肿瘤的治疗或预防方法
WO2025086243A1 (zh) * 2023-10-27 2025-05-01 深圳湾实验室坪山生物医药研发转化中心 白细胞受体酪氨酸激酶抑制剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001333A1 (en) 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
WO1989001478A1 (en) 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JPH0820584A (ja) 1994-07-04 1996-01-23 Takeda Chem Ind Ltd イミダゾール誘導体及びその用途
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP3519368B2 (ja) 1999-01-22 2004-04-12 麒麟麦酒株式会社 キノリン誘導体およびキナゾリン誘導体
PL203782B1 (pl) 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
DE122008000002I1 (de) 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
ATE362475T1 (de) 2003-12-31 2007-06-15 Schering Plough Ltd Bekämpfng von parasiten in tieren durch anwendung von imidazo(1,2-b)pyridazinderivaten
JP4935357B2 (ja) * 2004-11-08 2012-05-23 Ｍｓｄ株式会社 新規縮環イミダゾール誘導体
CA2594325A1 (en) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited Condensed imidazole compound and use thereof
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND

Also Published As

Publication number Publication date
AU2007279595A1 (en) 2008-02-07
PE20080538A1 (es) 2008-06-18
WO2008016192A3 (en) 2008-05-08
US8273741B2 (en) 2012-09-25
CO6150183A2 (es) 2010-04-20
US20100168424A1 (en) 2010-07-01
MA30651B1 (fr) 2009-08-03
US20090306374A1 (en) 2009-12-10
CL2007002261A1 (es) 2008-05-02
JP5238697B2 (ja) 2013-07-17
JP2009545583A (ja) 2009-12-24
EP2049541B1 (en) 2015-09-23
US20090137595A1 (en) 2009-05-28
AU2007279595A2 (en) 2009-03-19
IL196799A0 (en) 2009-11-18
CR10607A (es) 2009-03-12
WO2008016192A2 (en) 2008-02-07
NO20090986L (no) 2009-05-04
KR20090047509A (ko) 2009-05-12
US8034812B2 (en) 2011-10-11
AR062207A1 (es) 2008-10-22
CA2659971A1 (en) 2008-02-07
TW200817409A (en) 2008-04-16
US20100273788A1 (en) 2010-10-28
EP2049541A2 (en) 2009-04-22
MX2009001349A (es) 2009-04-17
US8044049B2 (en) 2011-10-25

Similar Documents

Publication Publication Date Title
BRPI0714665A2 (pt) Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
EA201491456A1 (ru) Соединения-ингибиторы raf
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
EA202192151A1 (ru) Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
MX2020011085A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim.
UA107951C2 (xx) Похідні імідазопіридину як інгібітори jak
NO20090295L (no) Substituerte heteroarylderivater
MX381994B (es) Inhibidor de janus quinasa.
AR110128A2 (es) Compuesto del grupo de las 3-(imidazoil)-pirazolo[3,4-b]piridinas, composición farmacéutica que lo comprende y método para preparar el mismo
CR11430A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpirimidin-2-aminas como inhibidores de cinasas janus
LT2794600T (lt) 2,3-dihidro-benzo[1,4]oksazino dariniai ir giminingi junginiai kaip fosfoinozitido-3 kinazės (pi3k) inhibitoriai, skirti gydymui, pavyzdžiui, reumatoidinio artrito
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CR20120469A (es) Compuesto de pirazol-4-il-heterociclil-carboxamida y métodos de uso
SG10201804026WA (en) Inhibitors of influenza viruses replication
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
BR112019007108A2 (pt) misturas herbicidas
UA115868C2 (uk) Гетероциклічні сполуки, лікарські засоби, які містять зазначені сполуки, їх застосування і способи їх одержання
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
DOP2011000107A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
MX2009012376A (es) Derivados de pirimidona sustituidos con heteroarilamida para el tratamiento de enfermedades neurodegenerativas.
GT200600081A (es) Derivados de acetilenno

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 4A E 5A ANUIDADES.